Publications by authors named "S Baka"
Purpose Of Review: Despite recent advances in immunotherapy treatment for metastatic, early-stage nonsmall cell lung cancer (NSCLC), palliative, adjuvant, neoadjuvant, and perioperative treatment options, further development is needed. Exploring new frontiers of immuno-oncology is necessary. Researchers are interested in a therapeutic vaccination model.
View Article and Find Full Text PDFTo study antimicrobial susceptibilities of genital mycoplasmas recovered from endocervical samples of reproductive-age, nonpregnant women ( = 8,336). For isolation and susceptibility testing, the Mycoplasma IST2 kit was used. As many as 2093 samples were positive for mycoplasmas.
View Article and Find Full Text PDFObjectives: Canakinumab, an interleukin-1 beta inhibitor, previously showed reduced lung cancer incidence and mortality (CANTOS). Here, we compare the efficacy/safety of canakinumab versus placebo in patients with advanced non-small cell lung cancer (NSCLC) who had progressed after platinum-based doublet chemotherapy (PDC) and immunotherapy.
Materials And Methods: CANOPY-2, a randomized, double-blind, phase 3 trial, enrolled adult patients with stage IIIB/IV NSCLC, without EGFR or ALK alterations, who had received one prior PDC regimen and one prior programmed death-1/programmed death-ligand 1 inhibitor and experienced subsequent disease progression.
Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015-2018 in Greece. The 'SUMMER' study: a retrospective multicenter chart review project.
Melanoma Res
April 2024
Article Synopsis
- This study focused on collecting real-world evidence about treatment patterns and patient profiles for advanced melanoma in Greece between January 2015 and January 2018, using data from six oncology clinics.
- A total of 225 patients were included, with a median age of 62.6 years; most were diagnosed with metastatic disease and had common metastatic sites in the lungs, lymph nodes, and liver.
- Treatment options mostly involved targeted therapy (53.3%) and immunotherapy (45.3%), with the most common first-line regimens being combinations of BRAF inhibitors with MEK inhibitors and anti-PD-1 monotherapy.
Melanoma is the most aggressive type of skin cancer. Half of melanoma cases are characterized by the mutation BRAF V600. The case presented concerns a 41-year-old patient with locally advanced melanoma, being positive in mutation BRAF V600.
View Article and Find Full Text PDF